The chemotherapy regimens for advanced pancreatic cancer are as follows: 1. For pancreatic cancer patients in good physical condition, the recommended first-line chemotherapy regimen is gemcitabine combined with white egg and white paclitaxel, with a median survival of about 8.5 months and major adverse effects such as neutropenia, neurotoxicity, and malaise; 2. Triplet chemotherapy regimens: including oxaliplatin and irinotecan combined with 5-fluorouracil, with a median survival of about 11.1 months, but toxicity is significantly increased, and the main adverse effects are neutrophil deficiency, neurotoxicity, malaise, and gastrointestinal reactions such as nausea, vomiting, abdominal pain, and diarrhea; 3. Gemcitabine combined with S1 or gemcitabine combined with capecitabine, compared with single-agent gemcitabine, the two-drug combination regimen can prolong progression-free survival and also improve the quality of life of patients. For pancreatic cancer patients in poor physical condition, the recommended chemotherapy regimen for first-line treatment is firstly, gemcitabine monotherapy, which can achieve a median survival of 5.6 months, followed by fluorouracil-based monotherapy, commonly S1 capsules, capecitabine or continuous infusion of 5-fluorouracil, all of which can improve the survival profile of patients. In general, for patients in poorer condition, only the best supportive therapy can be given to reduce suffering and improve quality of life.